Letreise Winkfield, MD
Family Medicine · Edinburg, TXNPI 1720095284
Payments from drug & device makers
Across 340 payments — averaging $15.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$860
- AbbVie$800
- Novo Nordisk$775
- Lilly USA, LLC$618
- AstraZeneca$441
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$208
- plus $2K from 31 others
What the payments were for
- Food & beverage$5,18598%
- Education$812%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 50 | $860 |
| AbbVie(2 entities) | 58 | $800 |
| Novo Nordisk | 56 | $775 |
| Lilly USA, LLC | 37 | $618 |
| AstraZeneca | 25 | $441 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 18 | $208 |
| Merck | 14 | $193 |
| Astellas Pharma US Inc | 10 | $179 |
| Johnson & Johnson(2 entities) | 9 | $172 |
| Amarin Pharma, Inc. | 11 | $150 |
| Bayer | 6 | $99 |
| Amgen(2 entities) | 6 | $89 |
| Esperion Therapeutics, Inc. | 5 | $79 |
| Redhill Biopharma Inc. | 5 | $76 |
| Axsome Therapeutics, Inc. | 3 | $52 |
| Paratek Pharmaceuticals, Inc. | 2 | $43 |
| Kowa Pharmaceuticals America, Inc. | 2 | $33 |
| Shire North American Group Inc | 2 | $32 |
| Otsuka America Pharmaceutical, Inc. | 1 | $30 |
| Eisai Inc. | 2 | $29 |
| Phathom Pharmaceuticals, Inc. | 2 | $28 |
| Exact Sciences | 1 | $28 |
| Scynexis, Inc. | 1 | $25 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $23 |
| Phadia US Inc. | 1 | $21 |
| Arbor Pharmaceuticals, Inc. | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| Quidel Corporation | 1 | $19 |
| Boston Scientific | 1 | $19 |
| Radius Health, Inc. | 1 | $18 |
| Acclarent, Inc | 1 | $15 |
| Novartis | 1 | $15 |
| Pfizer | 1 | $14 |
| Duchesnay USA Incorporated | 1 | $14 |
| Abbott | 1 | $12 |
| AMAG Pharmaceuticals, Inc. | 1 | $11 |
| Si-bone, Inc. | 1 | $10 |
How this compares
$5,266 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 55 | $81,948 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 67 | $76,570 |
| OzempicSemaglutide | 47 | $72,750 |
| Tresiba Flextouch U-200Insulin Degludec | 21 | $61,250 |
| XareltoRivaroxaban | 30 | $42,091 |
| Tresiba Flextouch U-100Insulin Degludec | 64 | $41,864 |
| FarxigaDapagliflozin Propanediol | 40 | $39,940 |
| MyrbetriqMirabegron | 32 | $38,653 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 26 | $29,331 |
| JanuviaSitagliptin Phosphate | 24 | $26,371 |
| LinzessLinaclotide | 21 | $25,179 |
| GemtesaVibegron | 11 | $12,450 |
| Icosapent Ethyl | 28 | $12,215 |
| VascepaIcosapent Ethyl | 17 | $12,037 |
| Mirabegron ErMirabegron | 13 | $8,687 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $618 | $81,94855 claims |
| Novo NordiskOzempic | $775 | $72,75047 claims |
| MerckJanumet Xr, Januvia | $193 | $55,70250 claims |
| Johnson & JohnsonXarelto | $172 | $42,09130 claims |
| AstraZenecaFarxiga | $441 | $39,94040 claims |
| Astellas Pharma US IncMyrbetriq | $179 | $38,65332 claims |
| AbbVieLinzess, Synthroid | $800 | $28,09352 claims |
| PfizerPaxlovid | $14 | $1,42917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Edinburg
- Ashley BoseEdinburg$2.8M
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.